• Explore /
  • Poster
  • / Updated results from phase II study of combination of hyper-CVAD (HCVAD) with ponatinib in frontline therapy of patients (pts) with Philadelphia chromosome-positive (Ph+) acute lymphoblastic leukemia (ALL).

Updated results from phase II study of combination of hyper-CVAD (HCVAD) with ponatinib in frontline therapy of patients (pts) with Philadelphia chromosome-positive (Ph+) acute lymphoblastic leukemia (ALL).

Abstract Poster

Authors

null

Koji Sasaki

The University of Texas MD Anderson Cancer Center, Houston, TX

Koji Sasaki , Hagop M. Kantarjian , Farhad Ravandi , Deborah A. Thomas , Jorge E. Cortes , Naveen Pemmaraju , Tapan M. Kadia , Nicholas James Short , Ghayas C. Issa , Rebecca S. Garris , Vicky Jeanis , H. Gal Moore , Guillermo Garcia-Manero , Gautam Borthakur , William G. Wierda , Evguenia Gachimova , Susan Mary O'Brien , Elias Jabbour

Sign-In to See More Abstracts, Journal Articles, Posters, Videos and Slides and to Bookmark Your Favorite Content.

Disclaimer

This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org

Poster Details

Meeting

2016 ASCO Annual Meeting

Session Type

Poster Session

Session Title

Hematologic Malignancies—Leukemia, Myelodysplastic Syndromes, and Allotransplant

Track

Hematologic Malignancies—Leukemia, Myelodysplastic Syndromes, and Allotransplant

Sub Track

Acute Leukemia

Clinical Trial Registration Number

NCT01424982

Citation

J Clin Oncol 34, 2016 (suppl; abstr 7036)

DOI

10.1200/JCO.2016.34.15_suppl.7036

Abstract #

7036

Poster Bd #

28

Abstract Disclosures

Similar Posters

First Author: Nicholas James Short

First Author: Elias Jabbour

First Author: Jeremy Chang

First Author: Nicholas James Short